ATE471518T1 - Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind - Google Patents

Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind

Info

Publication number
ATE471518T1
ATE471518T1 AT05762419T AT05762419T ATE471518T1 AT E471518 T1 ATE471518 T1 AT E471518T1 AT 05762419 T AT05762419 T AT 05762419T AT 05762419 T AT05762419 T AT 05762419T AT E471518 T1 ATE471518 T1 AT E471518T1
Authority
AT
Austria
Prior art keywords
target
molecules
modulating
interest
ligand
Prior art date
Application number
AT05762419T
Other languages
English (en)
Inventor
Pierre Martineau
Piona Dariavach
Original Assignee
Centre Nat Rech Scient
Univ Montpellier I
Univ Montpellier Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Montpellier I, Univ Montpellier Ii filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE471518T1 publication Critical patent/ATE471518T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Liquid Crystal Substances (AREA)
AT05762419T 2004-04-27 2005-04-25 Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind ATE471518T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404433A FR2869416B1 (fr) 2004-04-27 2004-04-27 Procede d'identification d'un ligand capable de moduler selectivement une cascade fonctionnelle impliquant une cible et ses applications pour le criblage a haut-debit de molecules d'interet.
PCT/FR2005/001020 WO2005106481A2 (fr) 2004-04-27 2005-04-25 Procede d'identification d'un ligand capable de moduler selectivement une cascade fonctionnelle impliquant une cible, et ses applications pour le criblage a haut-debit de molecules d'interet.

Publications (1)

Publication Number Publication Date
ATE471518T1 true ATE471518T1 (de) 2010-07-15

Family

ID=34945450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05762419T ATE471518T1 (de) 2004-04-27 2005-04-25 Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind

Country Status (9)

Country Link
US (1) US9110077B2 (de)
EP (1) EP1743178B1 (de)
JP (1) JP4814220B2 (de)
AT (1) ATE471518T1 (de)
CA (1) CA2564767C (de)
DE (1) DE602005021875D1 (de)
ES (1) ES2348478T3 (de)
FR (1) FR2869416B1 (de)
WO (1) WO2005106481A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
FR2929851B1 (fr) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
EP2752487A1 (de) 2013-01-03 2014-07-09 Sanofi Intrazelluläres Phänotypen-Screening

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1994015638A1 (en) * 1992-12-31 1994-07-21 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
WO1994025565A1 (en) * 1993-04-23 1994-11-10 Ariad Pharmaceuticals, Inc. HUMAN $i(SYK)
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
JP2002515744A (ja) * 1996-05-20 2002-05-28 シグナル ファーマシュウティカルズ，インコーポレイテッド マイトジェン活性化プロテインキナーゼｐ３８―２およびその使用方法
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP1180244A2 (de) * 1999-05-13 2002-02-20 Caliper Technologies Corporation High througput screening verfahren und vorrichtungen
AU6058500A (en) 1999-06-30 2001-01-31 Center For Blood Research, The Fusion protein and uses thereof
US6709839B1 (en) * 1999-09-24 2004-03-23 Rigel Pharmaceuticals, Inc. SYK-UBP proteins, compositions and methods of use
JP2003009899A (ja) * 2001-05-28 2003-01-14 New Industry Research Organization 化合物のスクリーニング方法
WO2003059943A2 (en) * 2002-01-18 2003-07-24 Karo Bio Ab Conformation-specific, protein kinase binding peptides and related methods and products
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2004020619A1 (en) * 2002-08-30 2004-03-11 Ingenium Pharmaceuticals Ag Modified phospholipase c-gamma-2, expression products, and non-human animal models comprising said genes, and therapeutic uses
ITRM20020588A1 (it) * 2002-11-21 2004-05-22 Lay Line Genomics Spa Metodo per isolare anticorpi intracellulari neutralizzanti di interazioni proteiche.

Also Published As

Publication number Publication date
CA2564767A1 (fr) 2005-11-10
FR2869416B1 (fr) 2007-01-12
JP4814220B2 (ja) 2011-11-16
US9110077B2 (en) 2015-08-18
ES2348478T3 (es) 2010-12-07
EP1743178B1 (de) 2010-06-16
WO2005106481A2 (fr) 2005-11-10
WO2005106481A3 (fr) 2006-11-02
FR2869416A1 (fr) 2005-10-28
EP1743178A2 (de) 2007-01-17
JP2007534954A (ja) 2007-11-29
US20080146453A1 (en) 2008-06-19
CA2564767C (fr) 2014-06-17
DE602005021875D1 (de) 2010-07-29

Similar Documents

Publication Publication Date Title
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
EA200800278A1 (ru) АНТИ-αβ-АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
DE602006016567D1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
DE60235079D1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
ATE517123T1 (de) Anti-gpr-9-6 und anti-teck gerichtete antikörper und verfahren zur identifizierung von modulatoren der gpr-9-6 und teck funktion
MA32838B1 (fr) Procede de modulation de l'activite antagoniste d'un anticorps monoclonal
WO2007008917A3 (en) Modulation of protein functionalities
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
EA201001734A1 (ru) Улучшенные связывающие молекулы на основе фибронектина и их применение
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
WO2009067546A3 (en) Lung cancer markers and uses thereof
AU2006205900A8 (en) Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
DE60329839D1 (de) Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
ATE471518T1 (de) Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind
WO2005047328A3 (en) Antibodies against secretoryleukocyte protease inhibitor
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO2007056411A3 (en) Method of producing pan-specific antibodies
DK1292710T3 (da) Fremgangsmåde til matrix-screening
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties